2014 to be transition year for Japan pharma

2014 will be marked as a transition year for the Japanese Pharma industry – but the year is bound to be painful both for innovators and generic companies due to the new regulations.

A new report released by India-based Bharat Book Bureau finds these regulations to be “decisive” in spurring generic penetration significantly, with the main beneficiary being the Japanese government (or society) and not the generic companies.

The implications of new price-reversions are going to have many facets and will change conventional business models. The report’s authors expect many support services industries - CMOs, CROs and other allied services industries to benefit from these structural changes, while API importers will suffer. They also expect consolidation and M&A activities to spur in Japan.